Immediate effect of intravitreal injection of bevacizumab on intraocular pressure

Purpose: To investigate the immediate effect of intravitreal injection of bevacizumab on intraocular pressure (IOP).

Methods: This was a prospective and nonrandomized study. A total of 291 eyes with macular edema or active chorioidal neovascularization were submitted to a single 1.25 mg (0.05 mL) bevacizumab intravitreal injection. Intraocular pressure was measured with an Icare® tonometer immediately before and after injection in a seated position. The presence of subconjunctival reflux was recorded. The fellow eye served as the control.

Results: Mean preoperative IOP was 18.0±5.9 mmHg in the treated eye versus 16.9±6.0 mmHg in the fellow eye. Mean postoperative IOP was 42.1±14.5 mmHg in the treated eye versus 17.5±6.0 mmHg in the fellow eye. The IOP variation was statistically significant in both cases and controls (P<0.001 and P=0.003, respectively), and this increase was higher in cases than in controls (P<0.001). Postoperative IOPs higher than 50 mmHg were achieved in 32.0% of the eyes. Subconjunctival reflux was present in 21.3% and determined a lower IOP rise (P<0.001). Tested variables (glaucoma, phakic status, and sex) did not have a statistically significant effect on IOP rise or subconjunctival reflux.

Conclusion: IOP increases with intravitreal bevacizumab injection, reaching 50 mmHg or more in about one third of patients. A higher IOP is expected if no subconjunctival reflux occurs. The baseline IOP does not influence the incidence of subconjunctival reflux. The clinical relevance of these facts has yet to be clarified.

Keywords: bevacizumab, intraocular pressure, intravitreal injection, Icare®

Introduction

Intravitreal injection of antivascular endothelial growth factors (VEGF) has assumed a growing role in the treatment of several vitreoretinal diseases in the last few years. Ranibizumab and aflibercept are the only approved anti-VEGF agents for the treatment of choroidal neovascularization resulting from age-related macular degeneration.1–3 In addition, ranibizumab has been approved for the treatment of macular edema associated with vein occlusion and diabetic macular edema.4,5 Despite this fact, the off-label use of bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA, USA) for these4–8 and other9,10 entities has become globally widespread because of its low cost and similar results.11

Issues concerning safety with the intravitreal use of these agents, particularly bevacizumab, are still being raised and widely discussed in scientific, managerial, and public circles. Ocular adverse effects are well known and include endophthalmitis, cataract, vitreous hemorrhage, retinal tear, and detachment.12 With regard to systemic adverse effects, bevacizumab and ranibizumab have been compared, with no significant difference found between the drugs in terms of rates of death or arteriothrombotic events.7

...
Given the addition of fluid into the vitreous cavity, an increase in intraocular pressure (IOP) should be expected after intravitreous anti-VEGF delivery. This is usually transient, but occasionally, it can persist. An acute IOP rise has been shown to decrease both optic nerve head and juxtapapillary retinal blood flow proportionally to the quantitative rise in IOP. The axonal transport to the optic nerve head has also been proved to be blocked by an acute IOP increase in animal models. Although the real consequences of these findings are not clear, possible ganglion cell loss cannot be underestimated, mostly in patients with previous glaucoma or other optic neuropathies.

This prospective study was meant to quantify the IOP rise that occurs immediately after intravitreal bevacizumab injection and to investigate potential risk factors associated with this rise.

**Methods**

A prospective and nonrandomized study of patients undergoing intravitreal injection of bevacizumab was conducted at the ophthalmology department of Hospital de São João in Oporto, Portugal, between June 1, 2011, and March 31, 2012. The study included patients who were at least 18 years of age and who had a diagnosis of active choroidal neovascularization or macular edema with clinical criteria for antiangiogenic treatment. Patients with previous ocular surgeries, with the exception of cataract surgery, or intravitreal injections of corticosteroids within the previous 3 months were excluded. Informed consent was obtained for each patient.

Intravitreal injections were given at the operating theater by 12 surgeons who were familiar with the procedure and used the same technique. In patients receiving unilateral anti-VEGF injections, the noninjected fellow eye served as a control.

Preoperative management was done according to our department’s protocol for the procedure. Every patient undertook prophylaxis with topical ofloxacin (3 mg/mL) four times a day for 3 days before the procedure. The topical instillation of 0.5% tropicamide hydrochloride, 2.5% phenylephrine hydrochloride was also performed 20 minutes before the intravitreal injection. In the operating theater, in a seated position and immediately before the procedure, five valid IOP measurements were taken with the Icare* on both eyes. The mean IOP obtained by the instrument was recorded.

Patients were placed in a supine position, and after topical instillation of 0.4% oxybuprocaine hydrochloride, 5% povidone iodine was applied over the eyelids and in the conjunctival sac. After lid speculum placement, the inferotemporal area of sclera to be injected was marked with a caliper measuring 3.5 or 4 mm from the surgical limbus, depending on whether the patient was pseudophakic or phakic, respectively. Using a 30-gauge needle on an insulin syringe, 0.05 mL (1.25 mg) bevacizumab was then injected through the pars plana into the vitreous cavity, using a nonbeveled incision technique. After injection, a sterile cotton swab was used to occlude and massage the injection site. Anterior chamber paracentesis was not performed in any case. The occurrence of subconjunctival reflux was recorded. Immediately after the procedure, the patient was placed in a seated position and IOP was measured and recorded bilaterally, using the already described method.

As soon as the IOP was measured, all patients were checked for hand motion vision at a distance of 50 cm with the noninjected eye occluded. Topical ofloxacin (3 mg/mL) was administered four times a day to all patients in the 5 days after the intravitreal injection.

All records from a computer database were reviewed, and the following additional data were collected: age, sex, history of glaucoma, phakic status, and vitreoretinal disease.

Data were analyzed using SPSS Statistics 17.0 (SPSS Inc., Chicago, IL, USA). Comparison between IOP before and after the procedure was made with paired Student’s t-test. The difference in IOP increase, regarding the presence of reflux, previous history of glaucoma, and phakic state, was compared using the Mann–Whitney and Kruskal–Wallis tests. The chi-square test was used to study the odds of achieving an IOP spike (defined by the authors as an IOP value above 50 mmHg) after injection, as well as the odds of occurrence of subconjunctival reflux.

**Results**

We included 291 eyes of 291 patients. The mean age was 75 years (ranging from 35–95 years), with 64.3% of the patients being women. One hundred seventy-one eyes were phakic, 114 were pseudophakic, and 6 were aphakic. Twenty-seven patients had previous history of glaucoma (Table 1). The most common reason for injection of bevacizumab was neovascular age-related macular degeneration (72.9%), followed by choroidal neovascularization secondary to pathological myopia (9.6%) (Figure 1).

Subconjunctival reflux was noticed in 21.3% of the procedures.

Treated eyes had a mean IOP before injection of 18.0±5.9 mmHg; after injection it was 42.1±14.5 mmHg ($P<0.001$). The mean rise of IOP was 28.6±13.8 mmHg (range, 0–69 mmHg) in the absence of reflux and 7.7±10.3 mmHg
Table 1: Patients’ demographics and characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Frequency, n</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean</td>
<td>75.40±12.17</td>
<td></td>
</tr>
<tr>
<td>Injected eye</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OD</td>
<td>148</td>
<td>50.9</td>
</tr>
<tr>
<td>OS</td>
<td>143</td>
<td>49.1</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>104</td>
<td>35.7</td>
</tr>
<tr>
<td>Female</td>
<td>187</td>
<td>64.3</td>
</tr>
<tr>
<td>Glaucoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>27</td>
<td>9.3</td>
</tr>
<tr>
<td>Absent</td>
<td>264</td>
<td>90.7</td>
</tr>
<tr>
<td>Phakic status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phakic</td>
<td>171</td>
<td>58.8</td>
</tr>
<tr>
<td>Pseudophakic</td>
<td>114</td>
<td>39.2</td>
</tr>
<tr>
<td>Aphakic</td>
<td>6</td>
<td>2.0</td>
</tr>
</tbody>
</table>

Abbreviations: OD, right eye; OS, left eye.

Discussion

The intravitreal injection of antiangiogenic agents has assumed, globally, a leading role in the treatment of a growing number of ophthalmologic conditions since 2005, when the intravitreal use of bevacizumab was first reported. An increase in IOP after this procedure is expected, and therefore issues regarding its safety, the necessity of IOP monitoring, and possible implications for operating theater dynamics have been raised.

The 291 patients enrolled in this study showed a mean IOP rise of 24.1 mmHg, with a final average IOP of 42.1 mmHg immediately after the intravitreal injection of bevacizumab. These results have been shown to be statistically significant compared to the baseline IOP and with the IOP rise that occurred in the noninjected eyes. Kim et al. investigated the short-term IOP changes immediately after intravitreal injection of anti-VEGF and found a higher mean IOP change of 30 mmHg from baseline. However, in addition to bevacizumab, Kim et al. also included other drugs in their study (namely, triamcinolone and ranibizumab) and different needle sizes (27, 30, and 32 gauge), which may explain this difference. All other previous studies on the same subject started their IOP measurements between 2 and 30 minutes after injection, therefore precluding any accurate comparisons with the present study that aimed to measure the IOP peak that occurs immediately after the injection.

Despite there being no injection made, a mean IOP rise of 0.6 mmHg was also noted and found to be significant in the control group. As previously reported, changes in body position are correlated to IOP variation, with higher readings seen in a supine versus a seated position. Given this, a possible explanation for the IOP rise in noninjected eyes might rely on the short period of time between the change from a supine to a seated position and the respective IOP reading. This was probably insufficient for the hydrostatic changes to occur and for the episcleral

Table 2: Risk factors for intraocular pressure higher than 50 mmHg and subconjunctival reflux

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Intraocular pressure higher than 50 mmHg, odds ratio (95% confidence interval)</th>
<th>Subconjunctival reflux, odds ratio (95% confidence interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>1.16 (0.67–2.01)</td>
<td>0.72 (0.38–1.36)</td>
</tr>
<tr>
<td>Phakic status</td>
<td>1.28 (0.74–2.22)</td>
<td>1.15 (0.61–2.18)</td>
</tr>
<tr>
<td>Glaucoma history</td>
<td>0.53 (0.19–1.15)</td>
<td>0.94 (0.33–2.67)</td>
</tr>
</tbody>
</table>
In this study, 32% of the patients had a postinjection IOP spike. This acute rise can induce damage to the optic nerve head by compromising its autoregulatory mechanisms and change the lamina cribrosa contour. An IOP spike was reported by Kim et al in 36% of cases. Hollands et al found it in 10% of the patients 2 minutes after intravitreal injection, which gives additional proof and support to the transient nature of this rise.

Despite the true long-term consequences of these extreme IOP elevations not being known, one should not underestimate their intrinsic deleterious potential, mainly in patients with glaucoma or other optic neuropathies. The possibility of using a postoperative paracentesis or topical pressure-lowering medications as prophylaxis should be considered. El Chehab et al have found that the prophylactic use of a fixed combination of timolol and brimonidine or dorzolamide and the single use of 1% apraclonidine could reduce the IOP spikes and their duration. The use of 250 mg acetazolamide 20 minutes before the intravitreal injection, however, has been proved to be ineffective.

None of the tested variables (history of glaucoma, male sex, and phakic status) previously suggested as possible risk factors for higher and more sustained OHT has proved to have a statistically significant effect on postinjection IOP in this study. This study, however, did not aim to evaluate the sustainability of OHT but addressed only the acute rise in pressure. In contrast, only 30 patients had a history of glaucoma; this small sample may explain the absence of a statistical effect of this variable on IOP spikes.

Subconjunctival reflux was reported in about a quarter of the patients and led to a lower IOP increase. This has proved to be significant when compared with the IOP rise in patients without this event. Lorenz et al reported reflux in 52.9% of cases using 30-gauge needles and concluded that there was a direct relationship between needle thickness and reflux grade and an inverse relationship between needle thickness and the frequency of paracentesis for acute reduction of the IOP. This higher reflux rate may be explained by the low threshold used by the authors when reporting subconjunctival reflux. When the eyes with reflux rate graded as 1 (0.01 mL) are withdrawn, their reflux rate falls to 21.7%, which is similar to our results. The amount of reflux is influenced by the incision technique, being lower with a beveled approach, in contrast to the nonbeveled approach in our study. The reflux rate may also be lower in some centers with the preoperative use of the Honan intraocular pressure reducer. This study did not quantify the reflux, which is an obvious limitation.
Neither of the studied variables were proved to have influence on the subconjunctival reflux rate. The small number of glaucoma patients in the study was, again, a statistical bias.

To the best of our knowledge, this is the largest prospective study performed evaluating the immediate effect of intravitreal injection of bevacizumab on IOP and the first study on this topic using the Icare® tonometer to measure intraocular pressures, which may limit any comparisons done with other published studies on the subject. The rebound tonometer shows a good correlation with the Goldmann applanation tonometer.37–40 However, central corneal thickness influences this agreement (overestimation of IOP with the Icare® tonometer).37 Some authors claim this correlation is affected by the IOP range, being less reliable for higher values,38 whereas others state the opposite.39 The Icare® tonometer is a portable, comfortable, and reliable solution19 to monitoring IOP and therefore seemed a suitable solution for operating theater environment use by the authors.

In conclusion, intravitreal injection of bevacizumab may induce a significant rise in IOP. Spikes of more than 50 mmHg may occur in about one third of the cases, which can cause damage to the optic nerve. Prevention of these pressure spikes should be considered not only in patients showing previous optic nerve damage, namely, those with advanced glaucoma, but also in patients with a history of multiple injections. To substantiate this opinion, however, additional studies addressing the possible loss of retinal ganglion cells with repeated intravitreal injections are needed.

Acknowledgment
We thank all colleagues who participated in the operating theater performing measurements of IOP.

Disclosure
The authors report no conflicts of interest in this work.

References


